Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Sell
9
MRNA Quote, Financials, Valuation and Earnings
Last price:
$40.15
Seasonality move
:
6.66%
Day range:
$39.79 - $41.49
52-week range:
$35.80 - $170.47
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.07x
P/B ratio:
1.29x
Volume:
4.8M
Avg. volume:
9.1M
1-year change:
-60.16%
Market cap:
$15.4B
Revenue:
$6.8B
EPS (TTM):
-$5.82
Analysts' Opinion
-
Consensus RatingModerna has received a consensus rating of Hold. The company's average rating is a Hold based on 7 Buy ratings, 12 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $127.09, Moderna has an estimated upside of 84.87% from its current price of $40.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $58.00 representing 100% downside risk from its current price of $40.13.
Fair Value
-
According to the consensus of 20 analysts, Moderna has 84.87% upside to fair value with a price target of $127.09 per share.
MRNA vs. S&P 500
-
Over the past 5 trading days, Moderna has overperformed the S&P 500 by 0.76% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Moderna does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Moderna has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Moderna reported revenues of $1.9B.
Earnings Growth
-
Moderna earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Moderna reported earnings per share of $0.03.
Enterprise value:
8.6B
EV / Invested capital:
0.72x
Price / LTM sales:
3.07x
EV / EBIT:
--
EV / Revenue:
1.70x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.17x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$3.4B
Return On Assets:
-12.92%
Net Income Margin (TTM):
-43.99%
Return On Equity:
-17.44%
Return On Invested Capital:
-17.44%
Operating Margin:
-3.77%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $20.7B | $9.1B | $5.1B | $1.8B | $1.9B | |
| Gross Profit | $16.2B | $3.4B | $3.4B | -$454M | $1.3B | |
| Operating Income | $13.3B | -$2.7B | -$2.7B | -$2B | -$70M | |
| EBITDA | $13.7B | -$1.8B | -$2B | -$1.7B | $79M | |
| Diluted EPS | $27.64 | -$9.35 | -$5.82 | -$9.53 | $0.03 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.6B | $13.4B | $14.3B | $10.8B | $9.7B | |
| Total Assets | $4.7B | $20.9B | $26.1B | $19.5B | $15.8B | |
| Current Liabilities | $1.5B | $10B | $6.8B | $4.4B | $2.2B | |
| Total Liabilities | $1.9B | $10.8B | $8.1B | $6B | $3.9B | |
| Total Equity | $2.8B | $10.1B | $18B | $13.5B | $11.9B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $6.6B | -$2.1B | -$3.2B | -$1.6B | -$1.6B | |
| Cash From Investing | -$5.3B | $3.7B | $2B | $789M | $721M | |
| Cash From Financing | -$3.9B | -$1.7B | -$50M | -$58M | $11M | |
| Free Cash Flow | $6.2B | -$2.7B | -$4B | -$1.7B | -$1.7B | |
MRNA
Sector
Market Cap
$15.4B
$45.9M
Price % of 52-Week High
23.54%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
-0.27%
-0.6%
1-Year Price Total Return
-60.16%
-32.15%
Beta (5-Year)
1.582
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$39.81
200-day SMA
Sell
Level
$90.21
Bollinger Bands (100)
Sell
Level
43.11 - 74.79
Chaikin Money Flow
Buy
Level
478.9M
20-day SMA
Sell
Level
$41.70
Relative Strength Index (RSI14)
Sell
Level
42.01
ADX Line
Buy
Level
10.15
Williams %R
Neutral
Level
-73.0261
50-day SMA
Sell
Level
$45.37
MACD (12, 26)
Sell
Level
-1.59
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
449.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.1628)
Buy
CA Score
(Annual)
Level (-0.0174)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-2.1882)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Stock Forecast FAQ
In the current month, MRNA has received 7 Buy ratings 12 Hold ratings, and 1 Sell ratings. The MRNA average analyst price target in the past 3 months is $127.09.
-
Where Will Moderna Stock Be In 1 Year?
According to analysts, the consensus estimate is that Moderna share price will rise to $127.09 per share over the next 12 months.
-
What Do Analysts Say About Moderna?
Analysts are divided on their view about Moderna share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Moderna is a Sell and believe this share price will drop from its current level to $58.00.
-
What Is Moderna's Price Target?
The price target for Moderna over the next 1-year time period is forecast to be $127.09 according to 20 Wall Street analysts, 7 of them rate the stock a Buy, 1 rates the stock a Sell, and 12 analysts rate the stock a Hold.
-
Is MRNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Moderna is a Hold. 12 of 20 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of MRNA?
You can purchase shares of Moderna via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Moderna shares.
-
What Is The Moderna Share Price Today?
Moderna was last trading at $40.15 per share. This represents the most recent stock quote for Moderna. Yesterday, Moderna closed at $40.13 per share.
-
How To Buy Moderna Stock Online?
In order to purchase Moderna stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 30
Lemonade [LMND] is down 3.32% over the past day.
Sell
50
TSLL alert for Dec 30
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 2.47% over the past day.
Buy
63
SMLR alert for Dec 30
Semler Scientific [SMLR] is down 4.69% over the past day.
